Bio-Techne joins Cell and Gene Therapy Catapult PAT consortium

By The Science Advisory Board staff writers

Bio-Techne is joining the Cell and Gene Therapy Catapult process analytical technology (PAT) consortium, which includes over 20 pharmaceutical companies, technology providers, therapy developers, and charities.

The consortium will assess the application and combination of multiple technologies for process analytics within the cell and gene therapy industry. Its first initiative is to unite companies and organizations from multiple industries to develop cell and gene therapy specific process analytical technologies.

These technologies will enable monitoring and control during the manufacturing process, including improving batch yields and lowering manufacturing costs. Consortium members will collaborate and share research findings to integrate and combine cell and gene therapy PAT into their respective offerings.

Copyright © 2021

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?